Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and Metabolomics

适用于蛋白质组学和代谢组学的 Orbitrap Elite 高分辨率质谱仪

• 批准号: 8334735
• 负责人: David H Hawke
• 金额: $ 87.74万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-22 至 2015-04-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8334735
• 关键词: Area; Biological Markers; Cancer Center; Cancer Patient; Cancer Research Project; Charge; Clinical; Complement; Diagnosis; Drug Targeting; Funding; Goals; Housing; Human; Hybrids; Ions; Label; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Mass Spectrum Analysis; Medical center; Medicine; Molecular; Outcome; Performance; Post-Translational Protein Processing; Proteins; Proteomics; Public Health; Resolution; Scanning; Speed; Staging; System; Texas; United States; United States National Institutes of Health; University of Texas M D Anderson Cancer Center; Validation; base; cancer therapy; improved; instrument; malignant breast neoplasm; mass spectrometer; metabolomics; molecular marker; outcome forecast; protein complex; protein metabolite; stable isotope; validation studies

DESCRIPTION (provided by applicant): We will use the LTQ-Orbitrap Elite (a linear ion-trap-orbital ion-trap hybrid mass spectrometer) to support a range of basic, translational, and clinical cancer research projects at the University of Texas M. D. Anderson Cancer Center (MDACC) and in collaborative studies in the Texas Medical Center (TMC). The Orbitrap Elite features include high mass resolution (>240,000), large space charge capacity, high mass accuracy (<3 ppm), a mass/charge range of up to 4000 m/z, and dynamic range greater than 103. The documented performance of the Orbitrap Elite exceeds that of most alternative instruments in three critical areas by at least one order of magnitude-resolution, mass accuracy, and scan speed. Those improvements make the Orbitrap the optimal mass spectrometer for proteomic and metabolomic platforms aimed at identification and validation of molecular markers. Its high-resolution, accurate mass capabilities previously could only be achieved with superconducting magnet systems. Importantly, those capabilities have made extraordinary contributions to the analysis of protein complexes, post-translational modifications, and biomarker discovery (identification of previously unidentified proteins and metabolites) as well as early-stage validation studies. The Orbitrap is especially suitable for studies employing stable isotope-dilution mass spectrometry or label-free quantification of proteins or metabolites. We expect that using the Orbitrap for molecular identification studies will imminently improve the diagnosis, treatment, and prognosis of human cancers, in keeping with the goal of the Kleberg Center for Molecular Markers (where the Proteomics Facility is housed) to improve the outcomes of cancer patients. We will use the proposed Orbitrap Elite in support of at least 7 NIH-funded R01, P01, and SPORE grantees and eventually many other NIH-funded projects at MDACC as well as in the TMC. Specifically, we plan to apply this new, improved mass spectrometer to the discovery of protein biomarkers in ongoing projects in breast, brain, ovarian, and prostate cancers. By identifying and validating such biomarkers and helping to identify new drug targets, the instrument will help us improve public health through improvements in the diagnosis and treatment of cancer. It will complement our functional proteomics-based personalized medicine initiatives in the Kleberg Center for Molecular Markers and eventually improve treatment of the large number of cancer patients treated each year at MDACC, the largest and top ranked cancer center in the United States.

描述（由申请人提供）：我们将使用LTQ-Orbitrap Elite（线性离子阱-轨道离子阱混合质谱仪）来支持一系列基础、转化和临床分析。 得克萨斯大学的癌症研究项目。D.安德森癌症中心（MDACC）和德克萨斯医学中心（TMC）的合作研究。Orbitrap Elite的特点包括高质量分辨率（> 240，000），大空间电荷容量，高质量精度（<3 ppm），质量/电荷范围高达4000 m/z，动态范围大于103。Orbitrap Elite的记录性能在三个关键领域超过大多数替代仪器，至少一个数量级的量级分辨率，质量准确度和扫描速度。这些改进使Orbitrap成为蛋白质组学和代谢组学平台的最佳质谱仪，旨在识别和验证分子标记。它的高分辨率，精确的质量能力以前只能通过超导磁体系统来实现。重要的是，这些能力为蛋白质复合物的分析、翻译后修饰和生物标志物发现（识别以前未识别的蛋白质和代谢物）以及早期验证研究做出了非凡的贡献。Orbitrap特别适用于采用稳定同位素稀释质谱法或蛋白质或代谢物的无标记定量的研究。我们预计使用Orbitrap进行分子鉴定研究将立即改善人类癌症的诊断，治疗和预后，与Kleberg分子标记中心（蛋白质组学设施所在地）的目标保持一致，以改善癌症患者的预后。我们将使用拟议的Orbitrap Elite来支持至少7个NIH资助的R 01、P01和SPORE受资助者，并最终支持MDACC和TMC的许多其他NIH资助的项目。具体来说，我们计划将这种新的、改进的质谱仪应用于正在进行的乳腺癌、脑癌、卵巢癌和前列腺癌项目中的蛋白质生物标志物的发现。通过识别和验证这些生物标志物并帮助识别新的药物靶点，该仪器将帮助我们通过改善癌症的诊断和治疗来改善公共健康。它将补充我们在Kleberg分子标记中心基于功能蛋白质组学的个性化医疗计划，并最终改善每年在美国最大和排名最高的癌症中心MDACC接受治疗的大量癌症患者的治疗。

项目成果

Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.

• DOI: 10.15252/msb.20145504
• 发表时间: 2015-01-21
• 期刊: Molecular systems biology
• 影响因子: 9.9
• 作者: Li X;Wang W;Wang J;Malovannaya A;Xi Y;Li W;Guerra R;Hawke DH;Qin J;Chen J
• 通讯作者: Chen J

Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects.

• DOI: 10.1186/s13073-021-00937-4
• 发表时间: 2021-08-28
• 期刊: Genome medicine
• 影响因子: 12.3
• 作者: Li Y;Zhang Y;Hu Q;Egranov SD;Xing Z;Zhang Z;Liang K;Ye Y;Pan Y;Chatterjee SS;Mistretta B;Nguyen TK;Hawke DH;Gunaratne PH;Hung MC;Han L;Yang L;Lin C
• 通讯作者: Lin C

Molecular characterization of exosome-like vesicles from breast cancer cells.

• DOI: 10.1186/1471-2407-14-44
• 发表时间: 2014-01-27
• 期刊: BMC cancer
• 影响因子: 3.8
• 作者: Kruger S;Abd Elmageed ZY;Hawke DH;Wörner PM;Jansen DA;Abdel-Mageed AB;Alt EU;Izadpanah R
• 通讯作者: Izadpanah R